Blood Res.  2017 Mar;52(1):67-69. 10.5045/br.2017.52.1.67.

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism

• Tavakoli V
• Naing S

• KMID: 2375208
• DOI: http://doi.org/10.5045/br.2017.52.1.67

Abstract

No abstract available.

MeSH Terms

Exons*
Thromboembolism*

Reference

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365:1054–1061. PMID: 15781101.

2. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011; 86:668–676. PMID: 21674578.

3. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009; 151:167–175. PMID: 19652186.

4. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016; 127:325–332. PMID: 26423830.

5. Alghasham N, Alnouri Y, Abalkhail H, Khalil S. Detection of mutations in JAK2 exons 12-15 by Sanger sequencing. Int J Lab Hematol. 2016; 38:34–41. PMID: 26361084.